Igm Biosciences Inc (IGMS) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access IGMS Annual Balance Sheets →
The table below presents a historical view of Igm Biosciences Inc's balance sheet, supporting analysis of financial position trends.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2025)
(Mar 31 2025) (Dec 31 2024) (Sep 30 2024) (Jun 30 2024)
Assets
Cash & cash equivalent30.65
Marketable Securities, Total MA73.66
Cash & Short-term Investments103.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current2.68
Total Current Assets106.99
Equipment/Property/Plant Net0.00
Other Assets, Noncurrent0.00
Restricted Cash-
Operating Lease Right Of Use Asset-
Total Assets106.99
Liabilities
Accounts Payable, Current AC2.40
Accrued Liabilities, Current AC3.66
Other Liabilities, Current0.00
Total Current Liabilities6.06
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
OperatingLeaseLiabilityNoncurrent-
Operating Lease Liability Current-
Total Liabilities6.06
Stockholders' Equity
Common Stock Value0.35
Additional Paid In Capital Common Stock1,072.67
Retained Earnings / Accumulated Deficit-972.35
Other Equity0.26
Common Stockholder's Equity100.93
Total Stockholder's Equity100.93
Liabilities & Stockholder's Equity106.99
4 historic quarters locked

Sign in to unlock the full Igm Biosciences Inc balance sheet history.

About Igm Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-25-100885

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.